Evidence map›Paper›PMID 42002612›Full record

ArticleScientific reports2026

Antibody profiling and plasma proteomics in SARS-CoV-2 infection: a pilot study.

Tetsuya Fukuda, Aya Nakayama, Yoko Chikaoka, Yasuhiko Bando, Takeshi Kawamura

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tetsuya FukudaResearch and Developments, Biosys Technologies, Inc., Tokyo, Japan. t-fukuda@biosys-tech.co.jp.
Aya NakayamaIsotope Science Center, The University of Tokyo, Tokyo, Japan.
Yoko ChikaokaIsotope Science Center, The University of Tokyo, Tokyo, Japan.
Yasuhiko BandoResearch and Developments, Biosys Technologies, Inc., Tokyo, Japan.
Takeshi KawamuraIsotope Science Center, The University of Tokyo, Tokyo, Japan. kawamura@lsbm.org.

Funding

Japan Agency for Medical Research and Development (AMED) 22nf0101638h0002
6 · The paper itself

Abstract

We present a pilot, single-subject longitudinal analysis of plasma antibodies and proteome dynamics across 310 days spanning COVID-19 vaccination and subsequent SARS-CoV-2 infection. Serial plasma samples were analyzed by DIA-LC-MS/MS, identifying 1502 proteins. Comparative analyses across key intervals (pre-vaccination, post-dose 1, post-dose 2, and post-infection) showed minimal proteomic shifts after vaccination but distinct, coordinated expression changes after SARS-CoV-2 infection.

Indexed as

Antibodies, ViralCOVID-19ProteomeProteomicsSARS-CoV-2HumansPilot ProjectsTandem Mass SpectrometryAntibodies, ViralProteomeCOVID-19Data-independent acquisition (DIA)Pilot studyPlasma proteomicsSARS-CoV-2

Identifiers

PMID42002612
PMCPMC13254294

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.